Patents Examined by John L Van Druff
-
Patent number: 11613588Abstract: The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosin Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.Type: GrantFiled: June 26, 2018Date of Patent: March 28, 2023Assignee: The Rockefeller UniversityInventors: Sohail F. Tavazoie, Masoud Tavazoie, Nils Henrik Halberg
-
Patent number: 11596635Abstract: The disclosure relates to compositions comprising diastereomer of a macrolide exhibiting improved therapeutic profile in the context of inhibiting cell proliferation compared to the corresponding compositions comprising mixture of diastereomers. The disclosure further provides drug-ligand conjugates formed using diastereomer of the macrolide. The disclosure also provides novel method of preparation of diastereomer of the macrolide and their therapeutic uses.Type: GrantFiled: November 13, 2018Date of Patent: March 7, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Thomas Nittoli, Nareshkumar F. Jain, Thomas Patrick Markotan
-
Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
Patent number: 11572408Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.Type: GrantFiled: March 14, 2018Date of Patent: February 7, 2023Assignee: Vaccinex, Inc.Inventors: Elizabeth Evans, Ernest Smith, Maurice Zauderer -
Patent number: 11478537Abstract: The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of sequences described in the specification.Type: GrantFiled: October 9, 2017Date of Patent: October 25, 2022Assignee: ENTEROME S.A.Inventors: Laurent Chene, Alban Mathieu, Matthieu Pichaud, Francesco Strozzi
-
Patent number: 11446289Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.Type: GrantFiled: August 28, 2019Date of Patent: September 20, 2022Assignee: ChemoCentryx, Inc.Inventors: Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
-
Patent number: 11446292Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.Type: GrantFiled: June 15, 2021Date of Patent: September 20, 2022Assignee: MedImmune LimitedInventors: Philip Wilson Howard, Niall Dickinson, Thais Cailleau, Luke Masterson, William Goundry
-
Patent number: 11440968Abstract: Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.Type: GrantFiled: July 17, 2017Date of Patent: September 13, 2022Assignee: OGD2 PHARMAInventors: Mickaël Terme, Jean-Marc Le Doussal, Mylene Dorvillius, Brigitte Assouline
-
Patent number: 11413353Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: November 23, 2016Date of Patent: August 16, 2022Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 11407825Abstract: Disclose herein are dosing regimens for targeted NaPi2b antibody-drug conjugates for treating cancer.Type: GrantFiled: August 16, 2019Date of Patent: August 9, 2022Assignee: Mersana Therapeutics, Inc.Inventors: Eric P. Hailman, Donna M. Jarlenski, Donald A. Bergstrom
-
Patent number: 11401345Abstract: The present disclosure provides humanized antibodies and antibody-drug conjugates that specifically bind to human tissue factor, and which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the disclosed humanized antibodies and antibody-drug conjugates in the treatment of cancer.Type: GrantFiled: November 26, 2018Date of Patent: August 2, 2022Assignee: Purdue Pharma L.P.Inventors: Daniel A. Soltis, Thomas Mehrling, Richard John Buick
-
Patent number: 11400094Abstract: Compounds according to formula II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.Type: GrantFiled: August 1, 2019Date of Patent: August 2, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam
-
Patent number: 11396543Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.Type: GrantFiled: April 28, 2020Date of Patent: July 26, 2022Assignee: ImmunoGen, Inc.Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
-
Patent number: 11357745Abstract: This document relates to methods and materials involved in treating a mammal having, or at risk of developing, cytokine release syndrome (CRS). For example, a mammal having, or at risk of developing, CRS can be treated by administering one or more biguanides (e.g., metformin) to the mammal.Type: GrantFiled: August 22, 2019Date of Patent: June 14, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: David Dingli, Ameet K. Mishra
-
Patent number: 11352436Abstract: The disclosure provides antigen binding proteins useful in the recognition of tumor cells and tumor specific delivery of drugs and therapies.Type: GrantFiled: February 9, 2018Date of Patent: June 7, 2022Assignee: Washington UniversityInventors: Dennis Hallahan, Vaishali Kapoor, Heping Yan
-
Patent number: 11291667Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.Type: GrantFiled: January 25, 2018Date of Patent: April 5, 2022Assignee: TURNING POINT THERAPEUTICS, INC.Inventors: Jingrong Jean Cui, Dayong Zhai
-
Patent number: 11285143Abstract: Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.Type: GrantFiled: March 8, 2017Date of Patent: March 29, 2022Assignee: Johnpro Biotech Inc.Inventors: Kwan-Hwa Chi, Yu-Shan Wang, Yi-Chun Huang, Hsin-Chien Chiang
-
Patent number: 11236160Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.Type: GrantFiled: October 10, 2017Date of Patent: February 1, 2022Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
-
Patent number: 11230598Abstract: Provided are methods involving combination therapy comprising administering to an individual in need thereof an antibody that preferentially depletes human B10 cells and an immune checkpoint inhibitor. Antibodies for use in the methods are also provided.Type: GrantFiled: June 14, 2019Date of Patent: January 25, 2022Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhiro Fujisawa, Jacquelyn Lykken
-
Patent number: 11214604Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: May 15, 2019Date of Patent: January 4, 2022Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 11208449Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 25, 2021Date of Patent: December 28, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh